Eli Samaha sold $119k of TBPH
owner at Theravance Biopharma, Inc.. 6,964 shares at an average of $17.14, traded Jul 6, 2026, filed Jul 8, 2026.
Score components
- +12Role10% owner
- +10Trade size$119k at market
- 0Share of holdings soldSold 0.1% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001877589-26-000002, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jul 6, 2026 | SOpen-market sale COMindirect: See Footnotes | -1,400 | $17.04 | $24k | 9,173,053 | Jul 8, 2026 |
| Jul 7, 2026 | SOpen-market sale COMindirect: See Footnotes | -5,564 | $17.17 | $96k | 9,167,489 | Jul 8, 2026 |
Related signals
Other insiders at Theravance Biopharma, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 8Weak | Theravance Biopharma, Inc. | Rhonda Farnum SVP, COMM & MEDICAL AFFAIRS | $227k 13,314 shares | -6% | |
| 45Moderate | Theravance Biopharma, Inc. | Eli Samaha owner | $5.8M 336,697 shares | -4% | |
| 15Weak | Theravance Biopharma, Inc. | Rhonda Farnum SVP, COMM & MEDICAL AFFAIRS | $218k 13,314 shares | -5% | |
| 17Weak | Theravance Biopharma, Inc. | Rhonda Farnum SVP, COMM & MEDICAL AFFAIRS | $434k 31,067 shares | -12% | |
| 27Weak | Theravance Biopharma, Inc. | Rhonda Farnum SVP, COMM & MEDICAL AFFAIRS | $583k 31,067 shares | -10% | |
| 17Weak | Theravance Biopharma, Inc. | Eran Broshy director | $590k 29,501 shares | -40% | |
| 12Weak | Theravance Biopharma, Inc. | Eran Broshy director | $809k 45,000 shares | -49% | |
| 25Weak | Theravance Biopharma, Inc. | Eran Broshy director | $1.1M 59,000 shares | -65% | |
| 5Weak | Theravance Biopharma, Inc. | Rhonda Farnum SVP, COMM & MEDICAL AFFAIRS | $114k 10,000 shares | -3% | |
| 8Weak | Theravance Biopharma, Inc. | Rhonda Farnum SVP, COMM & MEDICAL AFFAIRS | $264k 24,000 shares | -7% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.